Otsuka Pharmaceutical is broadening its scope in rare disease, striking a deal to acquire Jnana Therapeutics and its lead drug candidate, a small molecule on track for pivotal testing in a ...

BOSTON, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging ...

BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging ...

Jnana Therapeutics is hitting early-stage momentum, adding additional validation in the form of new cash and a fresh Big Pharma collaboration just as its lead metabolic disease asset launches into ...

(RTTNews) - Biotechnology company Jnana Therapeutics announced Tuesday that it has signed a strategic, multi-target collaboration and license agreement with Swiss drug maker Roche Group (RHHBY).

BOSTON--(BUSINESS WIRE)--Jnana Therapeutics today announced a strategic, multi-target collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery of small ...

TOKYO, Aug 1 (Reuters) - Japan's Otsuka Pharmaceutical (4578.T), opens new tab said on Thursday it agreed to pay more than $1 billion to acquire Jnana Therapeutics as it looks to expand its drug ...

Swiss pharma group Roche has doubled down on a partnership with Jnana Therapeutics, paying $50 million upfront to tap into the Boston-based biotech drug discovery platform for a wide-ranging push ...

Neurocrine Biosciences has teamed up with Jnana Therapeutics to develop drugs that target solute carrier (SLC) metabolite transporters. The collaboration gives Neurocrine a potential source of ...

Jnana Therapeutics Inc. has identified sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of diabetes, chronic kidney disease, ...